SAMIL PHARMACEUTICAL CO.,LTD
Financials
Valuation Metrics
SAMIL PHARMACEUTICAL CO.,LTD's Market Cap is ₩1458B. At end of 2025 it was ₩2102B. Ranked #1003 of 2,436 in KR market (top 41%), #508 of 787 on KOSPI (top 65%), #119 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 51%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 145.77B KRW | KR#1,003/2,436 Sec#119/234 |
| Revenue | 210.51B KRW | KR#990/2,436 Sec#55/234 |
| Net Income | -36.42B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 372.34B KRW | KR#891/2,436 Sec#52/234 |
| Net Assets | 128.56B KRW | KR#1,214/2,436 Sec#98/234 |
| Employees | 593 | KR#418/2,436 Sec#36/234 |
| Value | ||
| P/B | 1.13x | KR#1,590/2,436 Sec#106/234 |
| P/S | 0.69x | KR#1,143/2,436 Sec#55/234 |
| FCF Yield | -4.73% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -28.33% | KR#2,152/2,436 Sec#171/234 |
| ROA | -9.78% | KR#2,068/2,436 Sec#159/234 |
| Op. Margin | -11.98% | KR#2,022/2,436 Sec#138/234 |
| Revenue Growth | 0.50% | KR#1,413/2,436 Sec#135/234 |
| Financial Health | ||
| Debt Ratio | 189.63% | KR#1,626/2,436 Sec#184/234 |
| Total Debt | 163.89B KRW | KR#552/2,436 Sec#30/234 |
| FCF | -6.89B KRW | KR#1,592/2,436 Sec#129/234 |
| Cash | 1.19B KRW | KR#2,319/2,436 Sec#222/234 |
| Current Ratio | 0.46x | KR#2,276/2,436 Sec#223/234 |
| Performance | ||
| 1Y Return | -32.46% | KR#1,638/2,436 Sec#142/234 |
| 1M Return | -1.75% | KR#1,157/2,436 Sec#102/234 |
| From 52W High | -47.74% | KR#1,103/2,436 Sec#89/234 |
| 1Y MDD | -52.64% | KR#1,044/2,436 Sec#86/234 |
| Trading | ||
| Volume | 69,351 shares | KR#897/2,436 Sec#81/234 |
| Foreign Own. | 3.85% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | -1,679 KRW | KR—/2,436 Sec—/234 |
| BPS | 6,016 KRW | KR#1,304/2,436 Sec#94/234 |
Company Info
Samil Pharmaceutical, a mid-sized pharmaceutical company established in 1947 and listed on KOSPI in 1985, primarily develops, produces, and sells specialized and generic pharmaceuticals. The company also exclusively distributes directly imported original products in Korea. It operates a subsidiary with a global ophthalmic CDMO factory in Vietnam and has secured domestic sales rights for new drugs from Galmed and Biosplice. Samil Pharmaceutical is pursuing growth in new drug development and global CDMO business, headquartered in Seocho-gu, Seoul.